Skip to main content
OpenTrials
Completed

NCT Number: NCT03034603

The Safety and Efficacy Test of Nutri-PEITC Jelly in Head and Neck Cancer Patients

This triple-blinded randomized placebo control trial aims to investigate the safety and efficacy of Nutri-PEITC jelly, a functional food, in head and neck cancer patients. The primary outcome measure includes adverse events, health-related quality of life, tumor response and progression-free survival. The secondary outcome includes serum p53 and cytochrome C levels and functional status.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National cancer institute, Bangkok, Thailand

Loading trial locations.

About this study

Previously, Nutri-jelly, a novel edible nutritious gel for patients with chewing and swallowing difficulties, was shown to be effective in improving the quality of life of head and neck cancer patients. Recently, Nutri-PEITC jelly is recently developed by addition of Phenethyl Isothiocyanate (PEITC), a phytochemical compound with chemopreventive action in animal bearing oral cancer. It intends to be a functional food for cancer survivor. The dose of PEITC in Nutri-jelly was based on safe and effective dose determined in animal studies. Furthermore, Nutri-PEITC jelly was proven safe in healthy volunteers who daily consumes for a consecutive month with no serious adverse events. The purpose of this study is to determine safety and efficacy of Nutri-jelly with PEITC in head and neck cancer patients.

independent variable: continuous Nutri -jelly with PEITC intake dependent variable (outcome): adverse effects, health-related quality of life score, tumor response, progression-free survival, serum p53 and cytochrome C levels and functional status

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of squamous cell carcinoma in areas of lip, oral cavity, oropharynx and hypopharynx, who receive only palliative care or deny definitive treatment
  • Finished radiotherapy or/and chemotherapy for at least one month
  • Has at least one measurable target lesion
  • Baseline KPS ≥ 40% or ECOG 0-3
  • Blood tests are in acceptable ranges (neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L; Hb ≥ 9.0 g/dL), renal function (clearance creatinine using the CKD-EPI formula (Chronic Kidney Disease Epidemiology group) ≥50 mL/min) and hepatic function (SGOT , SGPT, serum bilirubin ≤ 1.5 of upper limits of normal
  • Able to take the intervention (through mouth or NG tube) without aspiration
  • Able to communicate and consent to the study

Exclusion criteria

  • Cannot come back for the follow-up visits
  • Receive or had received N-acetylcysteine during the intervention
  • Has systemic diseases that might interfere with the results
  • Chronic kidney disease that requires dialysis
  • Increased risk of aspiration pneumonia
  • Pregnancy or lactation
  • Untreated infectious diseases

Treatment and study plan

Nutri-jelly with PEITC

Dietary Supplement

Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.

Nutri-jelly

Dietary Supplement

Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.

Primary outcomes

  1. Adverse events

    Time frame: 1 month and 3 months after receiving intervention

    Evaluation of adverse events by physical examination, blood tests, and interviewing the subjects

  2. Changes in Health-related quality of life score compared to baseline

    Time frame: Baseline, 1 month and 3 months after receiving intervention

    Evaluation of Health-related quality of life by using questionnaire FACT-HN

  3. Changes in Tumor response compared to baseline

    Time frame: Baseline, 1 month, 3 months after receiving intervention

    Evaluation of tumor response following RECIST criteria at 1 month and 3 months

  4. Progression-free survival time

    Time frame: The time of the intervention until any signs or symptoms of progressive disease be recorded.

    The length of time during the intervention that the participant lives with stable disease

Secondary outcomes

  1. Serum p53 level

    Time frame: 1 month and 3 months after receiving intervention

    Level of both wild type and mutant p53 in serum

  2. Serum cytochrome C level

    Time frame: 1 month and 3 months after receiving intervention

    Level of cytochrome C in serum

  3. Changes in Functional status

    Time frame: Baseline, 1 month and 3 months after receiving intervention

    Evaluation of functional status using KPS (Karnofsky Performance Score) score

Sponsors and collaborators

Lead sponsor

Dental Innovation Foundation Under Royal Patronage

Other

Collaborators

  • Mahidol University
  • Ministry of Health, Thailand
  • Srinakharinwirot University

Registry information

Important dates

Study start
2014
Primary completion
2021
Study completion
2023
First posted
Jan 27, 2017
Registry last updated
Feb 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.